

# Microphysiological Systems at NCATS: Increasing the Predictivity of Translational Assays

Christopher P. Austin, M.D. Director, NCATS

Microphysiological Systems: Bridging Human and Animal Research

National Academy of Sciences Roundtable on Science and Welfare of Laboratory Animal Use

January 19, 2021



### **NCATS Mission**




To catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across human diseases and conditions.



# Improved (more predictive?) translational models/assays

2D Spheroids Organoids Printed Tissues Organ-on-a-chip



**HTS compatibility** 















#### Toxicology in the 21st Century



OVERVIEW -

HIGHLIGHTS

PROJECTS ▼

000


RESOURCES ▼

CONTACT

#### Tox21 Scientists Prioritize Compounds to Advance Research on Mitochondrial Damage

As part of the Tox21 collaboration, scientists developed of an analytical approach to enable researchers to prioritize environmental chemicals for their ability to disrupt mitochondria, the power generators of...

More





The Toxicology in the 21st Century (Tox21) Consortium is a federal collaboration between the U.S. Environmental Protection Agency (EPA), National Toxicology Program (NTP) headquartered at the National Institute of Environmental Health Sciences (NIEHS), National Center for Advancing Translational Sciences (NCATS), and Food and Drug Administration (FDA).

MORE






https://tox21.gov/



# Building a tissue biofabrication capability for disease modeling and drug screening





# **Tissue Chips for Drug Screening Program**

Establishment of NCATS December 2011

2010 - 2012

**Regulatory Science** 

NIH – FDA Joint

**Leadership Council** 

on

Advancing

**Regulatory Science** 

Micromachine was one

Common Fund \$18 M

RFA-RM-10-006

- Heart and Lung

of 4 awards

FDA \$2.25 M

IQ Consortium MPS Affiliate: AbbVie, Alnylam, Amgen, Astellas, AstraZeneca, Biogen, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Hoffman-La Roche, Janssen Pharmaceuticals, Merck & Co., Merck KGaA, Mitsubishi Tanabe, Novartis, Pfizer, Sanofi, Seattle Genetics, Takeda, Theravance, Vertex

#### **US Food and Drug Administration**

- DARPA \$75 M
- \* AstraZeneca. GlaxoSmithKline and Pfizer **Reference Set Compounds** (2014-2017)

2012 - 2017 **Toxicity Studies** 

#### **NCATS Tissue Chips for Drug** Screening

RFA-RM-11-022 - 10 awards

RFA-RM-12-001 - 8 awards

NCATS \$50 M

Common Fund, NIBIB, NCI, NICHD, NIEHS, **ORWH \$25 M** 

\* Center for Advancement of Science in Space (CASIS) or International Space Station -**National Laboratory** 

\$8 M in kind per launch

\* NASA task orders with implementation partners

2016 - 2021 **Accelerated Aging Models** 

#### **Tissue Chips in Space**

RFA-TR-16-019 - 5 awards \$12 M

RFA-TR-18-001 (with NIBIB)

- 4 awards \$10 M

#### **Nociception, Addiction, and Overdose**

RFA-TR-19-003

- 5 awards (\$25 M HEAL)

#### **Alzheimer's Disease-Related Dementias**

RFA-NS-19-027

- 1 award \$7.5 M (NCATS \$0.005 M)

#### **Disease Models**

RFA-TR-16-017

NHLBI, NIAMS, NIBIB, NICHD, NIDCR, NIDDK, NIEHS, NINDS, ORWH

- 13 awards \$75 M (NCATS \$32 M) RFA-DK-17-035 Type 2 Diabetes

3 awards \$15 M (NCATS \$0.015 M)

2016 - 2020 Building Confidence in MPS

**Self-sustaining** beyond NCATS support


Tissue Chips Testing Centers and Database Center RFA-TR-16-006, RFA-TR-18-005, RFA-TR-18-006 - 2 TCTCs and 1 MPS DbC \$24 M

#### Tissue Chips Consortium



# Why non-human animal MPS?

- Reduce, refine, replace animal use in research
- Evaluate environmental chemical effects on wildlife species
- Advance animal health (veterinary) research
- Bridge animal and human data to allow more robust translational/drug development/regulatory applications of MPS data





# NGATS

COLLABORATE. INNOVATE. ACCELERATE.









